Iobenguane
As of the edition of 20 October 2026, Iobenguane is a small molecule: marketed, first approved in 1994 (US); acts on SLC6A2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Adreview
- First approved
- 25 March 1994 (US)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- FUJIFILM Toyama Chemical; 8 holders in all
- Registered trials
- 30, 3 stopped early
- Disease areas
- Cancer; Heart and blood vessels; Mental health; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Iobenguane.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 2 | 0 | 0 |
| Phase 1 | 3 | 1 | 1 | 1 |
| Phase 2 | 9 | 3 | 2 | 1 |
| Phase 3 | 7 | 5 | 0 | 1 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 30 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GE Healthcare | Later holder and Lead sponsor of trials | 2008 to now |
| Pharmalucence | Acquired holder | 2008 to now |
| Lantheus Biosciences | Later holder and Lead sponsor of trials | 2018 to now |
| FUJIFILM Toyama Chemical | Applicant | 2021 to now |